Public money is finite, and research competes with claims that are more urgent

The argument

Proponents of this position argue that the case for more research funding is almost always made in isolation, as though the only question were whether research is valuable. Their claim is that this is the wrong question. Every pound a government spends is a pound it has taken in tax or borrowed, and the relevant comparison is not between funding research and funding nothing but between funding research and funding the next best use of the same money. Proponents argue that when the comparison is made honestly, research does badly against several alternatives. The benefits of a research budget are uncertain, diffuse and arrive decades later, whereas the benefits of a treated patient, a repaired road or a smaller class arrive now and can be identified. They add that much of what is already known is not applied for want of money: treatments exist that are not delivered, engineering solutions exist that are not built, and public health measures exist that are not funded. On this account a government facing that situation should be closing the gap between knowledge and practice rather than widening the stock of knowledge it is failing to use. They add that the distributive question matters too. Proponents argue that the people who pay for research funding through taxation are the general population, while its immediate beneficiaries are a highly educated profession and the firms that later commercialise its results, so an increase transfers money from the many to the few on the promise of eventual general benefit. The argument concludes that because public funds are limited and have competing claims that are more certain and more urgent, scientific research should not receive more of them.

Premises

Counter-arguments

Critics reply that the comparison the argument demands cuts the other way once the time horizon is honest, since the treatments being delivered today exist only because research was funded when its payoff was equally uncertain, and refusing on those grounds in every period guarantees there is nothing to deliver later. They add that research budgets are small relative to health, welfare and defence spending, so an increase would not meaningfully displace the urgent claims described. On the distributive point, critics argue that the benefits of research are about as widely shared as any form of public spending, since everyone uses the medicine, the materials and the forecasting that result.

Rejecting the premises

[Rejecting P1] The comparison is sound but incomplete, since the next best use of the money must be assessed over the same horizon, and a choice made this way in every period leaves nothing to deliver later. [Rejecting P2] The treatments and infrastructure counted as certain benefits exist only because earlier research was funded when its payoff was equally uncertain. [Rejecting P3] Research budgets are small relative to health, welfare and defence spending, so an increase would not meaningfully displace the urgent claims described. [Rejecting C] At most it follows that spending should be prioritised carefully, not that research is the item to hold down.